Oxford Biomedica PLC

Directors Dealings / Market Share Purchases

RNS Number : 3173M
Oxford Biomedica PLC
13 September 2019
 

 

 

Directors Dealings / Market Share Purchases

 

Oxford, UK - 13 September 2019: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that the Company's Chief Financial Officer and a Non-Executive Director have both increased their shareholdings in the Company through the purchase of shares.  

 

Stuart Paynter, Chief Financial Officer of the Group, has purchased 3,395 ordinary shares of 50p each ("Ordinary Shares") in the Company on 13 September 2019 on the London Stock Exchange at a price of 585.6p. Following this purchase Stuart Paynter holds 6,770 shares representing 0.009% of the Company.

 

Stuart Henderson, Non-Executive Director of the Group, has purchased 1,248 Ordinary Shares in the Company on 13 September 2019 on the London Stock Exchange at a price of 557.0p. Following this purchase Stuart Henderson holds 7,925 shares representing 0.01% of the Company.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 

 1.

Details of the person discharging material responsibilities/person closely                 associated

 

 a.

Name

 Stuart Paynter

 

 2.

Reason for the notification

 

 a.

Position/status

 Chief Financial Officer

 b.

Initial notification /amendment

 Initial notification

 

3.

Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor

 

 a.

Name

 Oxford Biomedica plc

 

 b.

Legal Entity Identifier

 213800S1GVQNXQ15K851

 

4.

Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 a.

Description of the financial instrument, type of instrument identification code

 Oxford Biomedica plc Ordinary Shares of 50p each

 

 

 GB00BDFBVT43

 

b.

Nature of the transaction

 Purchase of ordinary shares

 

c.

Currency

 GBP - British Pound

 

d.

Price(s) and volume(s)

 

Price(s)

 

 

Volume(s)

£5.86

3,395

 

 

 

 

e.

Aggregated information

·      Aggregated volume

·      Price

·      Aggregated total

 

 

3,395

 

 £5.8562

 £19,881.80

 

f.

Date of the transaction

 2019-09-13

 

g.

Place of the transaction

 London Stock Exchange, Main Market (XLON)

 

 

 

 1.

Details of the person discharging material responsibilities/person closely                 associated

 

 a.

Name

 Stuart Henderson

 

 2.

Reason for the notification

 

 a.

Position/status

 Non-Executive Director

 b.

Initial notification /amendment

 Initial notification

 

3.

Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor

 

 a.

Name

 Oxford Biomedica plc

 

 b.

Legal Entity Identifier

 213800S1GVQNXQ15K851

 

4.

Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 a.

Description of the financial instrument, type of instrument identification code

 Oxford Biomedica plc Ordinary Shares of 50p each

 

 

 GB00BDFBVT43

 

b.

Nature of the transaction

 Purchase of ordinary shares

 

c.

Currency

 GBP - British Pound

 

d.

Price(s) and volume(s)

 

Price(s)

 

 

Volume(s)

£5.57

1,248

 

 

 

 

e.

Aggregated information

·      Aggregated volume

·      Price

·      Aggregated total

 

 

1,248

 

 £5.57

 £6,951.36

 

f.

Date of the transaction

 2019-09-13

 

g.

Place of the transaction

 London Stock Exchange, Main Market (XLON)

 

 

 

The issued share capital of the Group is 76,767,971 ordinary 50p shares.

 

 

-Ends-

 

For further information, please contact:

 

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 480 people. Further information is available at www.oxb.com

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHLLFLFAIIVLIA